Clinical efficacy of anlotinib combined with radiotherapy in the treatment of advanced lung adenocarcinoma with epidermal growth factor receptor mutation
Objective To investigate the clinical efficacy of anlotinib combined with radiotherapy in the treatment of advanced lung adenocarcinoma with epidermal growth factor receptor(EGFR)mutation.Method According to different treatment methods,100 patients with EGFR mutant advanced lung adenocarcinoma were divided into control group and observation group,with 50 cases in each group.The control group received radiotherapy,while the observation group re-ceived radiotherapy combined with anlotinib treatment.The short-term and long-term efficacy,incidence of adverse reac-tions,levels of tumor markers[carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),neuron specific eno-lase(NSE),cyto-keratin 19 fragment antigen 21-1(CYFRA21-1)],fatty acid synthetase(FAS),and tumor M2 pyruvate ki-nase(TuM2-PK)were compared between the two groups.Result The objective response rate of the observation group was 90.00%,which was higher than 74.00%of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of NSE,CYFRA21-1,CA125,CEA,FAS,and TuM2-PK in both groups were lower than those before treatment,and the levels of NSE,CYFRA21-1,CA125,CEA,FAS,and TuM2-PK in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The total incidence of ad-verse reactions in the observation group was 6.00%,and there was no statistically significant difference compared to 10.00%in the control group(P>0.05).The average progression-free survival(PFS)of the observation group was(9.82±2.03)months,which was significantly longer than(7.36±1.23)months of the control group,and the difference was statisti-cally significant(P<0.01).Conclusion Anlotinib combined with radiotherapy has good clinical efficacy in the treatment of EGFR mutant advanced lung adenocarcinoma,which can effectively reduce tumor marker levels,prolong PFS,and do not increase the risk of adverse reactions.
NETL
NSTL
万方数据
